Summary
Short answer: as of 2026, a licensed US compounding pharmacy generally cannot lawfully compound TB-500 (thymosin beta-4). Federal law lets a pharmacy compound from a bulk substance only if it clears one of three sourcing paths under Section 503A(b) — and TB-500 fails all three: it has no USP monograph, it is not a component of an FDA-approved drug, and it sits in Category 2 on the FDA's 503A bulks list rather than on the permitted side. 503B outsourcing facilities can't supply it either. This FAQ walks through each path and what would have to change.
Key Takeaways
- A pharmacy may only compound from a bulk substance that clears one of three 503A(b) sourcing paths — and TB-500 clears none of them.
- TB-500 (thymosin beta-4) has no USP or NF monograph, so the first path is unavailable.
- TB-500 is not a component of any FDA-approved drug, so the second path is closed.
- TB-500 was placed in Category 2 on the FDA 503A bulks list — the tier the FDA says should not be used in compounding during review.
- 503B outsourcing facilities face an even stricter list, so they cannot lawfully supply TB-500 either.
- Any clinic advertising "compounded TB-500" in 2026 is operating outside the 503A framework — the same pattern seen with BPC-157 compounding.
- A July 2026 FDA advisory committee is reviewing peptide compounding, but its recommendation is non-binding and nothing has changed yet.
The short answer
No — as of 2026, a licensed US compounding pharmacy generally cannot lawfully compound TB-500 (thymosin beta-4). This isn't a matter of a cautious pharmacist; it follows directly from the structure of federal compounding law. Because there is no FDA-approved TB-500 drug to reformulate, any compounding would have to begin from raw active ingredient — a bulk drug substance — and bulk substances are the most tightly controlled starting material in the entire system.
Section 503A of the Federal Food, Drug, and Cosmetic Act permits compounding from a bulk substance only when it clears at least one of three defined sourcing paths. TB-500 misses on every one. For the plain-English version of that rule, see what Section 503A is; for the broader legal picture on this peptide, see is TB-500 legal in 2026?.
This is not legal or medical advice
This article explains the general federal framework as of 2026 for educational purposes. TB-500 is sold for research use only and is not for human consumption. Regulatory status changes and state rules vary — confirm current status against primary FDA sources before acting.
How TB-500 fails all three 503A paths
The Drug Quality and Security Act of 2013 (DQSA) formalized FDA oversight of compounding after a deadly 2012 meningitis outbreak. It created Section 503A for traditional, patient-specific pharmacy compounding and Section 503B for larger outsourcing facilities. Under 503A(b), a bulk drug substance qualifies only if it clears one of three alternative paths — and only one is needed. TB-500 clears none.
Path 1 — no USP or NF monograph
A USP monograph is a published, enforceable quality standard defining identity, strength, purity, and testing for a substance. TB-500 has no applicable USP or NF monograph — there is no official standard for what pharmaceutical-grade thymosin beta-4 even is — so the first path is simply unavailable.
Path 2 — not a component of an approved drug
The second path allows compounding from a bulk substance that is an active ingredient in an FDA-approved product. TB-500 has never been the subject of an approved new drug application and is not an ingredient in any approved drug, so there is nothing for this path to attach to. This mirrors the situation described in research peptides vs prescription peptides.
Path 3 — Category 2 on the bulks list
The third path is the FDA's 503A bulks list. Nominated substances are sorted, on an interim basis, into Category 1 (may be used in compounding during review) or Category 2 (the FDA identified significant safety concerns and says they should not be used in compounding during review). TB-500 was placed in Category 2 — it is on the list, but on the wrong side of it.
| 503A(b) sourcing path | What it requires | TB-500 status |
|---|---|---|
| USP / NF monograph | An official pharmacopeial quality standard exists | No monograph — path unavailable |
| Component of an approved drug | It is an active ingredient in an FDA-approved product | Never approved; not a component of any approved drug |
| On the FDA 503A bulks list | Listed as permitted (Category 1) during review | On the list but in Category 2 — should not be compounded |
503A vs 503B: outsourcing facilities can't supply it either
A natural follow-up is whether a larger, more heavily regulated compounder — a 503B outsourcing facility — could step in. The answer is still no. Section 503B facilities operate under current good manufacturing practice (cGMP) and can produce batches without a patient-specific prescription, but they are bound by an even more restrictive bulk-substance rule. For the fuller contrast, see what Section 503B is.
A 503B facility may generally compound from a bulk substance only if there is a clinical need for it and it appears on the FDA's separate 503B bulks list, or if it is used to address a drug shortage. TB-500 is not on the 503B list and is not a shortage drug, so the outsourcing route is a narrower gate, not a workaround. The same analysis applies to its close cousin — see can pharmacies compound BPC-157?.
Category 1 vs Category 2 in one line
Category 1 = may be used in compounding while the FDA reviews it. Category 2 = the FDA flagged significant safety concerns and says it should not be used in compounding during review. TB-500 is in Category 2.
Marketing does not equal legality
The existence of a product for sale — even from a business that looks clinical — does not mean it is lawfully compounded or that it meets any pharmaceutical quality standard. TB-500 remains research use only and is not for human consumption.
Timeline
2012
Meningitis outbreak
A deadly outbreak traced to contaminated compounded injections exposes gaps in compounding oversight and prompts congressional action.
2013
Drug Quality and Security Act
Congress formalizes FDA oversight of compounding, creating the 503A (patient-specific) and 503B (outsourcing facility) framework and the interim bulk-substance category system.
2020–2023
TB-500 placed in Category 2
The FDA sorts several research peptides — including TB-500 (thymosin beta-4), BPC-157, Ipamorelin, CJC-1295, and GHK-Cu — into Category 2 of the 503A interim bulk substances list, citing safety and characterization concerns.
April 15, 2026
FDA announces advisory committee
The FDA announces it will convene an advisory committee to reconsider compounding restrictions on several peptides.
July 23, 2026
Advisory committee meets
The committee is scheduled to review the evidence and issue a non-binding recommendation. Any resulting change to Category 2 status would still be months away.
Frequently Asked Questions
Can a compounding pharmacy legally make TB-500 in 2026?
Generally no. Under Section 503A, a pharmacy may compound from a bulk substance only if it has a USP monograph, is a component of an FDA-approved drug, or is on the FDA's approved 503A bulks list. TB-500 meets none of these and sits in Category 2, so lawful compounding is not available.
Is TB-500 the same as thymosin beta-4?
TB-500 is the common research name for a synthetic peptide closely associated with thymosin beta-4 (Tβ4). For regulatory purposes it is treated as thymosin beta-4, and it is that substance the FDA placed in Category 2 on the 503A interim bulks list.
What are the three 503A sourcing paths?
A bulk drug substance must (1) be the subject of an applicable USP or NF monograph, (2) be a component of an FDA-approved drug, or (3) appear on the FDA's 503A bulks list as permitted. Meeting any one is enough — but TB-500 fails all three.
Why can't a 503B outsourcing facility supply TB-500?
503B facilities face an even stricter rule: they may generally compound from a bulk substance only if it is on the 503B bulks list or addresses a drug shortage. TB-500 is on neither, so outsourcing facilities cannot lawfully supply it either.
What does Category 2 mean for TB-500?
Category 2 is an interim FDA designation meaning the agency identified significant safety concerns and takes the position that the substance should not be used in compounding while under review. It is the specific mechanism that keeps TB-500 out of legitimate pharmacies.
Why do some clinics advertise compounded TB-500 anyway?
Most are selling it as a research-use-only chemical not for human consumption, are operating outside the compounding framework, or are dispensing it in contravention of the Category 2 designation. A compliant 503A pharmacy will not compound a Category 2 substance.
What would have to change for pharmacies to compound TB-500?
One of the three paths would need to open: the USP would publish a monograph, an FDA-approved TB-500 drug would come to exist, or the FDA would move TB-500 off Category 2. Each is a substantial regulatory step, and none happens quickly.
Is TB-500 treated differently from BPC-157?
Not for compounding purposes. Both are in Category 2 with no USP monograph and no approved-drug link, so both fail all three 503A paths. The analysis is essentially identical, as detailed in our BPC-157 compounding explainer.
References
- Drug Quality and Security Act of 2013, Pub. L. No. 113-54 (establishing FDA oversight of compounding under FD&C Act §§ 503A and 503B).Source
- U.S. FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (interim policy and category lists).Source
- U.S. FDA. Bulk Drug Substances for Use in Compounding by Outsourcing Facilities Under Section 503B of the FD&C Act.Source
- United States Pharmacopeia (USP). Compounding Standards and Monographs.Source
Research & Educational Use Only
This article is for general educational and informational purposes only and is not legal, medical, or regulatory advice. Laws and FDA policy change; verify the current status of any compound with primary FDA sources and a qualified professional before acting. Peptides discussed here are sold for research use only and are not intended for human consumption, diagnosis, treatment, or prevention of disease.